<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Senseonics Holdings, Inc. — News on 6ix</title>
<link>https://6ix.com/company/senseonics-holdings-inc</link>
<description>Latest news and press releases for Senseonics Holdings, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/senseonics-holdings-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d782dc51cc36e475342918.webp</url>
<title>Senseonics Holdings, Inc.</title>
<link>https://6ix.com/company/senseonics-holdings-inc</link>
</image>
<item>
<title>Senseonics Announces European Launch of Eversense® 365, The World’s First and Only One Year CGM System</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/senseonics-announces-european-launch-of-eversenser-365-the-worlds-first-and-only-one-year-cgm-system</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/senseonics-announces-european-launch-of-eversenser-365-the-worlds-first-and-only-one-year-cgm-system</guid>
<pubDate>Fri, 24 Apr 2026 11:00:00 GMT</pubDate>
<description>The next-generation CGM is now available in Sweden, with launches expected in Germany, Spain and Italy during the coming weeks as part of a phased roll out Eversense 365 doubles sensor lifespan from the previously available Eversense E3, extending the unique features and benefits of long-term implantable CGM use from six months to a full year GERMANTOWN, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manuf</description>
</item>
<item>
<title>First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of Wear</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/first-ever-real-world-evidence-of-eversense-365-presented-at-attd-demonstrates-sustained-performance-and-positive-impact-throughout-one-year-of-wear</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/first-ever-real-world-evidence-of-eversense-365-presented-at-attd-demonstrates-sustained-performance-and-positive-impact-throughout-one-year-of-wear</guid>
<pubDate>Sat, 14 Mar 2026 04:00:00 GMT</pubDate>
<description>New data shows positive real-world impact of the world’s first and only one-year CGM, with a full year of strong patient adherence, glucometrics and</description>
</item>
<item>
<title>Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/senseonics-holdings-inc-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/senseonics-holdings-inc-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched</description>
</item>
<item>
<title>Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/sequel-med-tech-and-senseonics-launch-transformative-combination-of-twiisttm-and-eversenser-365</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/sequel-med-tech-and-senseonics-launch-transformative-combination-of-twiisttm-and-eversenser-365</guid>
<pubDate>Thu, 19 Feb 2026 13:00:00 GMT</pubDate>
<description>The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetesMANCHESTER, N.H. and GERMANTOWN, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing transformative drug delivery technologies, and Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on long-term, implantable Continuous Glucose Monitoring (CGM) systems for people with diabetes, today announced full availability of the</description>
</item>
<item>
<title>Senseonics Receives European Approval for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/senseonics-receives-european-approval-for-eversense-365-worlds-longest-lasting-continuous-glucose-monitor</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/senseonics-receives-european-approval-for-eversense-365-worlds-longest-lasting-continuous-glucose-monitor</guid>
<pubDate>Thu, 29 Jan 2026 05:00:00 GMT</pubDate>
<description>GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and</description>
</item>
<item>
<title>Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/senseonics-holdings-inc-to-participate-at-the-btig-13th-annual-medtech-digital-health-life-science-and-diagnostic-tools-conference</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/senseonics-holdings-inc-to-participate-at-the-btig-13th-annual-medtech-digital-health-life-science-and-diagnostic-tools-conference</guid>
<pubDate>Wed, 28 Jan 2026 21:05:00 GMT</pubDate>
<description>GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, Utah. To request a meeting with Senseonics, investo</description>
</item>
<item>
<title>Senseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business Update</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/senseonics-announces-preliminary-unaudited-revenue-for-fourth-quarter-2025-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/senseonics-announces-preliminary-unaudited-revenue-for-fourth-quarter-2025-and-provides-business-update</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>Preliminary unaudited revenue expected to be approximately $14.2 million for Q4 2025, an increase of 71% year-over-year Introduced 2026 revenue guidance of</description>
</item>
<item>
<title>Senseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor (CGM) with twiist™ Automated Insulin Delivery (AID) System</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/senseonics-announces-first-commercial-patients-using-eversense-365-continuous-glucose-monitor-cgm-with-twiisttm-automated-insulin-delivery-aid-system</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/senseonics-announces-first-commercial-patients-using-eversense-365-continuous-glucose-monitor-cgm-with-twiisttm-automated-insulin-delivery-aid-system</guid>
<pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
<description>twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM GERMANTOWN, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Senseonics</description>
</item>
<item>
<title>Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare Conference</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/senseonics-holdings-inc-to-participate-in-the-stifel-2025-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/senseonics-holdings-inc-to-participate-in-the-stifel-2025-healthcare-conference</guid>
<pubDate>Mon, 10 Nov 2025 13:05:00 GMT</pubDate>
<description>GERMANTOWN, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel 2025 Healthcare Conference, being held in New York, NY. 2025 Stifel Healthcare Conference Format: Fireside chat and one-on-one meetingsDate: Wednesday, November 12, 2025T</description>
</item>
<item>
<title>Senseonics Announces Transfer to Nasdaq Stock Exchange</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/senseonics-announces-transfer-to-nasdaq-stock-exchange</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/senseonics-announces-transfer-to-nasdaq-stock-exchange</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>GERMANTOWN, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and</description>
</item>
<item>
<title>Senseonics Holdings, Inc. Reports Third Quarter Financial Results</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/senseonics-holdings-inc-reports-third-quarter-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/senseonics-holdings-inc-reports-third-quarter-financial-results</guid>
<pubDate>Wed, 05 Nov 2025 21:05:00 GMT</pubDate>
<description>Generated Q3 revenue of $8.1 million, representing year-over-year growth of 90% Achieved a 160% increase in U.S. new patient starts over prior year Planning for the transition of CGM commercial responsibility from Ascensia Diabetes Care back to Senseonics GERMANTOWN, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems</description>
</item>
<item>
<title>Senseonics Holdings, Inc. Schedules Third Quarter 2025 Earnings Release and Conference Call for November 5, 2025 at 4:30 P.M. Eastern Time</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/senseonics-holdings-inc-schedules-third-quarter-2025-earnings-release-and-conference-call-for-november-5-2025-at-430-pm-eastern-time</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/senseonics-holdings-inc-schedules-third-quarter-2025-earnings-release-and-conference-call-for-november-5-2025-at-430-pm-eastern-time</guid>
<pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
<description>GERMANTOWN, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development</description>
</item>
<item>
<title>Senseonics Announces Preliminary Unaudited Revenue for Third Quarter 2025 and Provides Business Update</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/senseonics-announces-preliminary-unaudited-revenue-for-third-quarter-2025-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/senseonics-announces-preliminary-unaudited-revenue-for-third-quarter-2025-and-provides-business-update</guid>
<pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
<description>Preliminary unaudited revenue of $8.1 million for Q3 2025 Generated record quarterly new patient starts in Q3 2025 Established reverse stock split ratio of</description>
</item>
<item>
<title>Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/senseonics-signs-memorandum-of-understanding-with-ascensia-diabetes-care-to-take-over-commercialization-and-distribution-of-eversense-365</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/senseonics-signs-memorandum-of-understanding-with-ascensia-diabetes-care-to-take-over-commercialization-and-distribution-of-eversense-365</guid>
<pubDate>Wed, 03 Sep 2025 04:00:00 GMT</pubDate>
<description>CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt</description>
</item>
<item>
<title>Senseonics Holdings, Inc. Reports Second Quarter Financial Results</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/senseonics-holdings-inc-reports-second-quarter-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/senseonics-holdings-inc-reports-second-quarter-financial-results</guid>
<pubDate>Wed, 06 Aug 2025 04:00:00 GMT</pubDate>
<description>Generated Q2 revenue of $6.6 million, representing year-over-year growth of 37% Achieved a 79% increase in U.S. new patient starts over prior year GERMANTOWN,</description>
</item>
<item>
<title>Senseonics Holdings, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for August 6, 2025 at 4:30 P.M. Eastern Time</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/senseonics-holdings-inc-schedules-second-quarter-2025-earnings-release-and-conference-call-for-august-6-2025-at-430-pm-eastern-time</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/senseonics-holdings-inc-schedules-second-quarter-2025-earnings-release-and-conference-call-for-august-6-2025-at-430-pm-eastern-time</guid>
<pubDate>Wed, 16 Jul 2025 04:00:00 GMT</pubDate>
<description>GERMANTOWN, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development</description>
</item>
<item>
<title>Senseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event at ADA 2025: Eversense® 365 Continuous Glucose Monitoring System for People with Diabetes</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/senseonics-holdings-inc-to-host-in-person-and-virtual-analyst-event-at-ada-2025-eversenser-365-continuous-glucose-monitoring-system-for-people-with-diabetes</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/senseonics-holdings-inc-to-host-in-person-and-virtual-analyst-event-at-ada-2025-eversenser-365-continuous-glucose-monitoring-system-for-people-with-diabetes</guid>
<pubDate>Wed, 04 Jun 2025 20:05:00 GMT</pubDate>
<description>GERMANTOWN, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it will host an in-person and virtual analyst event in conjunction with the American Diabetes Association 85th Scientific Sessions (ADA 2025), on Saturday, June 21, 2025 at 8:00am CT at the Marriot Marquis Chicago.</description>
</item>
<item>
<title>Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters’ Option to Purchase Additional Shares, and Closing of Private Placement</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/senseonics-holdings-inc-announces-closing-of-public-offering-including-exercise-in-full-of-the-underwriters-option-to-purchase-additional-shares-and-closing-of-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/senseonics-holdings-inc-announces-closing-of-public-offering-including-exercise-in-full-of-the-underwriters-option-to-purchase-additional-shares-and-closing-of-private-placement</guid>
<pubDate>Wed, 21 May 2025 04:00:00 GMT</pubDate>
<description>Public offering results in gross proceeds of $57.5 millionPrivate placement results in gross proceeds of approximately $20.3 million GERMANTOWN, Md., May 21,</description>
</item>
<item>
<title>Senseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private Placement</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/senseonics-announces-pricing-of-dollar50-million-public-offering-of-common-stock-and-concurrent-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/senseonics-announces-pricing-of-dollar50-million-public-offering-of-common-stock-and-concurrent-private-placement</guid>
<pubDate>Thu, 15 May 2025 04:00:00 GMT</pubDate>
<description>GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and</description>
</item>
<item>
<title>Senseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private Placement</title>
<link>https://6ix.com/company/senseonics-holdings-inc/news/senseonics-announces-commencement-of-dollar50-million-public-offering-of-common-stock-and-concurrent-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/senseonics-holdings-inc/news/senseonics-announces-commencement-of-dollar50-million-public-offering-of-common-stock-and-concurrent-private-placement</guid>
<pubDate>Thu, 15 May 2025 04:00:00 GMT</pubDate>
<description>GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and</description>
</item>
</channel>
</rss>